News
Public · Published
MRNA: Higher revenue guidance and positive Phase 3 melanoma results mark a stronger quarter
Moderna reported that third-quarter revenue rose 29% year over year to $1.313 billion and net income was $162 million, compared with a loss a year earlier. It raised its 2026 revenue growth guidance to 15–25% and said intismeran produced positive Phase 3 melanoma results.
Published:
Updated:
What happened
Moderna reported that third-quarter revenue rose 29% year over year to $1.313 billion and net income was $162 million, compared with a loss a year earlier. It raised its 2026 revenue growth guidance to 15–25% and said intismeran produced positive Phase 3 melanoma results.
Confirmed
Global impact / market context
Higher guidance points to management expecting stronger revenue growth in 2026, while the quarterly profit contrasts with the prior-year loss. Positive Phase 3 results may support future development of intismeran, but the summary gives no launch timing or expected sales, so commercial impact remains uncertain.
Analyst inference
The update combines reported financial improvement with a clinical result, but the article provides no share-price response, sales breakdown, or trial detail. Investors therefore cannot tell from this information how much growth depends on existing products versus future contributions from intismeran.
Analyst inference
What to watch
- Track whether upcoming reports show revenue growth consistent with the raised 15–25% outlook, and whether net income remains positive after the reported third-quarter improvement. Analyst inference
- Look for further details on intismeran’s Phase 3 melanoma results, including whether Moderna outlines next development steps or a possible regulatory filing. Analyst inference
- Watch for disclosures that connect the raised 2026 revenue outlook to specific products or explain expected costs, since neither detail appears in the supplied summary. Analyst inference
Evidence
- Original source link unavailable